Claims for Patent: 10,478,471

Summary for Patent: 10,478,471

Title:	Immunotherapy against several tumors including gastrointestinal and gastric cancer
Abstract:	A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
Inventor(s):	Fritsche; Jens (Dusslingen, DE), Weinschenk; Toni (Aichwald, DE), Walter; Steffen (Reutingen, DE), Lewandrowski; Peter (Tuebingen-Hirschau, DE), Singh; Harpreet (Munich, DE)
Assignee:	IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)
Application Number:	16/502,268
Patent Claims:	1. A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide, wherein said peptide consists of the amino acid sequence of VFIFKGNQF (SEQ ID NO: 18), wherein the peptide is in a complex with an MHC molecule. 2. The method of claim 1, wherein the T cells are autologous to the patient. 3. The method of claim 1, wherein the T cells are obtained from a healthy donor. 4. The method of claim 1, wherein the T cells are derived from tumor infiltrating lymphocytes or peripheral blood mononuclear cells. 5. The method of claim 1, further comprising expanding T cells in vitro. 6. The method of claim 1, wherein the MHC molecule is a class I molecule. 7. The method of claim 1, wherein the composition further comprises an adjuvant. 8. The method of claim 7, wherein the adjuvant is selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. 9. The method of claim 1, wherein the activated T cells are cytotoxic T cells produced by contacting T cells, in vitro, with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide. 10. The method of claim 9, further comprising stimulating the activated T cells in the presence of an anti-CD28 antibody and IL-12 to clonally expand the T cells. 11. The method of claim 1, wherein the patient has gastric cancer. 12. The method of claim 1, wherein the patient has gastrointestinal cancer. 13. The method of claim 1, wherein the patient has colorectal cancer. 14. The method of claim 1, wherein the patient has pancreatic cancer. 15. The method of claim 1, wherein the patient has lung cancer. 16. The method of claim 1, wherein the patient has renal cancer. 17. The method of claim 7, wherein the adjuvant comprises IL-2. 18. The method of claim 7, wherein the adjuvant comprises IL-7. 19. The method of claim 7, wherein the adjuvant comprises IL-15. 20. The method of claim 7, wherein the adjuvant comprises IL-21.

Details for Patent 10,478,471

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2030-03-19